Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

For Julie Cohen, a diagnosis of multiple myeloma wasn't just a medical hurdle — it was a profound shift in perspective. Initially searching for a cure, she soon realized that navigating a high-risk, ...

March weather becomes a metaphor for survivorship as a mother describes anxiety, relief and uncertainty patients with cancer ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...

Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...

CURE spoke with incoming ASCO president Dr. Deb Schrag on elevating the patient voice, humanism in care and why partnership ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

A phase 3 global trial is enrolling previously treated locally advanced/metastatic nonsquamous NSCLC to define DATROWAY ...

Active surveillance (“watch and wait”) functioned as a strategy to monitor biology while preserving sequencing flexibility ...

Cancers Symposium, and the updates were full of hope for people with advanced prostate cancer. CURE highlights two studies ...